This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S et al. High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011; 29: 3214–3223.
Borges VF, Elias AD . The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest. J Clin Oncol 2011; 29: 3205–3206.
Elfenbein GJ . Stem-cell transplantation for high-risk breast cancer. N Engl J Med 2003; 349: 80–82.
André T, Boni C, Mounedji-Boudiaf L . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–2351.
Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005; 366: 1935–1944.
Marino P, Roché H, Moatti JP . PEGASE Group. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis. Am J Clin Oncol 2008; 31: 117–124.
Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 2006; 17: 588–596.
Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 2008; 19: 861–870.
Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA et al. Prognostic model for relapse after high dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002; 20: 707–718.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Castagna, L., Martino, M. Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?. Bone Marrow Transplant 48, 305 (2013). https://doi.org/10.1038/bmt.2012.126
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.126